Expression, purification and biological effect of a novel single chain Fv antibody and protamine fusion protein for the targeted delivery of siRNAs to FGFR3 positive cancer cells

Zang, Chongsen; Liu, Zixuan; Yang, Kunmeng; Li, Rui; Wang, Xinxin; Zhang, Jizhou; Xiao, Yong

doi:10.1016/j.ejbt.2017.05.009

Cited by 1 publication

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ScFv-9R can both bind siRNA and deliver siRNA into FGFR3 positive cancer cells via silencing specific gene expression to suppress tumor growth (Zhang et al 2014). Afterwards, we created another fusion protein, R3P, which is composed of ScFv and protamine (Zang et al 2017). R3P, like ScFv-9R, can deliver siRNA into FGFR3 positive cancer cells.…”

Section: Introductionmentioning

confidence: 99%

Construction and characterization of immunoliposomes targeting fibroblast growth factor receptor 3

Zheng

Zong

et al. 2019

AMB Expr

Self Cite

View full text Add to dashboard Cite

Fibroblast growth factor receptor 3 (FGFR3) plays an important regulatory role in tumor cell proliferation and drug resistance. FGFR3 is often constitutively active in many tumors. To deliver drugs into tumor cells by targeting FGFR3 will be a promising and potential strategy for cancer therapy. In this study, a novel fusion protein, ScFv-Cys containing a single chain variable fragment (ScFv) and an additional C-terminal cysteine residue, was generated at a rate of 10 mg/L of bacterial culture and purified at 95% by Ni-NTA chromatography. Subsequently, the recombinant ScFv-Cys was coupled with malPEG2000-DSPE and incorporated into liposomes to generate the immunoliposomes. The results indicated that immunoliposomes can specifically deliver the fluorescent molecules, Dio into bladder cancer cells highly expressing FGFR3. In conclusion, we successfully generated FGFR3-specific immunoliposomes, and proved its targeting effect and delivering ability.

show abstract

Section: Introductionmentioning

confidence: 99%